Manchenko Dina
- New
- 12 years of experience
- Ukraine, Uzhhorod, Expert Clinic
Experience
2021 year - 2022 year
Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital
2021 year - 2022 year
Department of Radiation Oncology, Biruni University Faculty of Medicine
2020 year - 2021 year
Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital
2017 year - 2020 year
Clinical Manager of Radiation Oncology, Neolife Medical Center
2016 year - 2017 year
Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine
2011 year - 2016 year
Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine
2010 year - 2011 year
Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine
2008 year - 2010 year
Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)
2006 year
Medical Faculty, Dokuz Eylül University
2006 year - 2008 year
Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)
2000 year - 2006 year
Medical Faculty, Dokuz Eylül University
Education
2022 year
Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor
2022 year
Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism
2021 year
Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor
2017 year
Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member
2017 year
Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor
2006 year
Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service
2006 year
Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization
1998 year
Ege University, Faculty of Medicine
Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.
Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.
Dr. Sullivan graduated in Medicine and Surgery from the National University of Rosario in 2005, specializing in Medical Oncology through the MIR at the Santa Creu i Sant Pau Hospital (HSCiSP, 2012) in Barcelona.
She received a post-MIR scholarship from the Ministry of Interior from HSPiSP (2012) and then a pre-doctoral scholarship from ISCiii (Rio Hortega – 2013-2015).
In 2014, he moved to Paris where he obtained a DUERTECC diploma at the Gustave Roussy University Hospital (Villejuif), followed by an ESMO scholarship (Georges Mathé Translator Scholarship), which he received in 2016.
Since January 2017, he has been working on the staff of the Medical Oncology Department of the HSCiSP. In the same year, he obtained his PhD from the Autonomous University of Barcelona.
Since 2015, he has been a member of the Board of Directors of the Spanish Lung Cancer Group (GECP). And since 2022, he has been the coordinator of the HSCiSP Committee on Neuroendocrine Tumors.
In November 2021, she joined the IOR Medical Oncology Service and is actively involved in various research projects in the Pangea Lab under the supervision of Dr. Molina.
Dr. Sullivan is involved in several clinical trials in lung cancer and neuroendocrine tumors, many of which have been presented at various international scientific meetings.
She has participated in national and international conferences and is an author and co-author of research articles published in influential journals.
She is currently a member of the Spanish Society of Medical Oncology (SEOM), GECP, European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).
Known Expertise
Medical Oncologist
Academic Position
Senior Lecturer
Education
Bar-Ilan University, Israel / Computational Biology
Israeli Society for Health-Tech / Fellowship by IMA/ Innovation and Entrepreneurship in Medicine and Health-Tech
Sheba Medical Center and Bar-Ilan University, Israel/ Genomics and Biomedical Informatics
Semmelweis University/Doctor of Medicine
Training and Specialization
Clinical observership in acute oncology, early phase clinical trials and lung cancer/ Guy's and St. Thomas hospital, London, England
Leader Shift, Executive Development Program, Tel-Aviv Sourasky Medical Center
Fellowship Program in Innovation and Entrepreneurship in Medicine and Health-Tech
Resident, Medical Oncology, TASMC, Israel
6th year medical school rotations, Kaplan Medical Center, Israel
Rotation, intensive care unit and pulmonology, Stony Brook hospital, NY, US
Clinical Experience
Leader of the TASMC oncology project of PSIFAS, the Israeli National Genomic Medicine Initiative
PI for study initiator trial: T-Cell Repertoire sequencing as clinical efficacy tool for pembrolizumab (with platinum based chemotherapy) in advanced NSCLC.
PI for study initiator trial: T-cell repertoire sequencing as a clinically efficacy tool for neoadjuvant immunotherapy plus platinum-doublet chemotherapy for resectable NSCLC.
Representative of the National Medical Association for the National Council for the Prevention, Diagnosis and Treatment of Malignant Diseases, as well as head of the oncology field, Leumit HMO
Consultant on drugs and operations in the field of oncology, Leumit HMO
Member of the Helsinki Committee for Clinical Studies, TASMC
Primary investigator (PI) in pharmaceutical phases I&III clinical trials Head of oncology day-care service, TASMC, Israel
Molecular Tumor Board (MTB) moderator of the Israeli Lung Cancer Society
NGS interpretation clinic alongside head of pathology, TASMC, Israel
PI for study initiator trial: Genomic Variant of BCL-2 as a Novel Predictor of Response to Paclitaxel, TASMC, Israel
Medical oncology clinic in the field of lung and breast cancer, TASMC, Israel
Leading sub-investigator (SI) in many phase I-III clinical trials in oncology, including intra-tumoral injections (mRNA, viruses and NO), TASMC, Israel
Courses
Good Clinical Practice ICH GCP R2 & Israeli MOH Guidelines Updated Course
Point-of-Care Ultrasound course, Israeli Medical Association
GCP training Bioforum
GCP training Bioforum
Investigator Site Personnel ICH GCP Training Certificate - TransCelerate BioPharma
Academic Experience
Lecturer in the Department of Medical Education at the Faculty of Medical and Health Sciences at Tel Aviv University
JIMS Journal Club - Instructor for students.
Guidance of Dr. Aviv Berkovich M.D in basic science: cfDNA NGS for identification ofprimary and acquired resistance in patients with Lung Cancer and EGFR mutations.
TASMC, Israel in collaboration with The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, NY USA
Training team for oncology residents, TASMC, Israel
Mentor for new intern, TASMC, Israel
Tutor for medical students in oncology clerkships, Tel-Aviv University, Israel
Honors
Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel
Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel
Sign of honor for reserve medical personnel for the battle in Lebanon, IDF
Completion of residency final examination (shlav Beit) with honors
Israeli society for clinical oncology and radiation therapy (ISCORT) 17 research grant competition winner
Affiliations
Israeli Medical Association (IMA)
Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT)
The Israeli Lung Cancer Group (ILCG)
European Society of Medical Oncology (ESMO)
International Association for the Study of Lung Cancer (IASLC)
The International Society of Liquid Biopsy (ISLB)
The Israeli Society for Health-Tech
Boards
Co-founder, board member and treasurer of the Israeli Acute Oncology Society
Clinical Research Association Board of Directors on behalf of the Israeli Lung Cancer Group
Member of the Trustees of Oncology Innovation, TASMC, Israel
Doctor of Medical Service IDF
Areas of interest
Thoracic malignancies,
early to late phase clinical trials,
intra-tumoral injections,
comprehensive genomic profiling of tumors,
liquid biopsies: cfDNA, TCR rep-seq and epi-Genetics;
cell therapy
20 top ranked Pancreatic neuroendocrine tumors doctors in the world are represented on this page. The list includes only verified specialists known for their experience and high success rates.
The ranking is composed according to the Bookimed patient reviews and considers the rating of hospitals where doctors practice.
Top 5 Pancreatic neuroendocrine tumors doctors on Bookimed.com:
The specialist’s CV contains details about the doctor’s expertise and work experience, education, scientific research, and languages spoken. Compare information on several specialists, read carefully about their experience, success rates, and methods they apply. Make sure the chosen doctor has relevant experience in the treatment of a medical issue you are looking for. Read reviews of patients who had a consultation with the chosen specialist.
Famous Pancreatic neuroendocrine tumors doctors have vast experience, continue education constantly, participate in professional associations and have positive feedback from patients treated.
The price for the consultation on Pancreatic neuroendocrine tumors varies between experts and depends on certain factors, such as:
To schedule your visit, just submit a request on Bookimed.com. Our coordinator will contact you to discuss the time and details of the appointment, so everything will go smoothly.
We can help to find the right doctors for Pancreatic neuroendocrine tumors if you have any difficulties with a choice. Bookimed services are free for patients ♥
One of the best cancer specialists in Europe, educator, and cancer researcher, President of the Central European Cooperative Oncology Group (CECOG).
Has published over 600 scientific papers on cancer treatment.
Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.
Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.
Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.
Coping with gastrointestinal and lung cancer without chemotherapy. Specialists at the Tel Aviv Sourasky Clinic (Ichilov) use an ultra-modern innovative method to combat neuroendocrine tumors. It is based on radionuclide therapy with the radioisotope Lutetium 177 (Lutetium-177). This innovation is a real breakthrough in oncotherapy, because in recent decades the number of cases of this type of cancer has been rapidly growing.
This method is completely new in the world. Today it exists only in Israel, Germany and Sweden.
Its essence is in the use of a new radiopharmaceutical - Lutetium 177 PRRT. The drug is administered intravenously at intervals of 7-8 weeks. With the help of Lutetium, cancer cells are destroyed selectively, without affecting healthy tissues of the body. That is, this method of treatment can literally be called "local radiation therapy". In addition, the drug does not have a toxic effect on the bone marrow and kidneys, destroying the tumor from the inside.
In addition, the use of this method allows patients to avoid severe side effects of chemotherapy, such as vomiting, nausea, pain, alopecia, weakness. It is also important that the treatment is carried out by a special group of medical specialists. Among them: leading doctors, nurses and medical physicists!
All of them work under the supervision of Dr. Inna Ospovat, a leading specialist in the nuclear therapy department at the Ichilov Clinic.
Education
2000-1994 Faculty of Medicine in Vitebsk, Belarus.
Specialization
2003 - 2011 - specialization in oncology and radiation therapy at the Hadassah University Hospital in Jerusalem.
Recognized experience
Oncology and radiation therapy
Additional education
2015 - PMH University Hospital (Totonto) Childhood irradiation and head and neck tumors
Attending conferences
About 10 presentations at medical conferences
Trade union membership
Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.
She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.
Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.
Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.
She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.
Education
Experience
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Specializations
Cancer Surgery
Pancreatic Surgery
Bile Duct Surgery
Bariatric Metabolic Surgery
Oncological Surgery
Breast Surgery
Gastric cancer
Colon cancer
Thyroid Cancer
Obesity Surgery
Diabetes Surgeries